290 related articles for article (PubMed ID: 17993595)
1. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
2. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
Saleh AW; Hillen HF; Duits AJ
Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
[TBL] [Abstract][Full Text] [Related]
3. Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells.
Haynes J; Obiako B; King JA; Hester RB; Ofori-Acquah S
Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1679-85. PubMed ID: 16714363
[TBL] [Abstract][Full Text] [Related]
4. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.
Ghatpande SS; Choudhary PK; Quinn CT; Goodman SR
Exp Biol Med (Maywood); 2008 Dec; 233(12):1510-7. PubMed ID: 18849548
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
6. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
8. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
9. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
10. MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease.
Zhao Y; Schwartz EA; Palmer GM; Zennadi R
FASEB J; 2016 Mar; 30(3):1171-86. PubMed ID: 26631480
[TBL] [Abstract][Full Text] [Related]
11. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention.
Marcus SJ; Ware RE
J Pediatr Hematol Oncol; 1999; 21(5):407-11. PubMed ID: 10524455
[TBL] [Abstract][Full Text] [Related]
12. Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients.
Kargutkar N; Nadkarni A
Expert Rev Hematol; 2023; 16(9):685-692. PubMed ID: 37394969
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmaco-proteomic analysis of hydroxyurea induced changes in the sickle red blood cell membrane proteome.
Ghatpande SS; Choudhary PK; Quinn CT; Goodman SR
J Proteomics; 2010 Jan; 73(3):619-26. PubMed ID: 19914412
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo.
Zennadi R
PLoS One; 2014; 9(10):e110306. PubMed ID: 25330306
[TBL] [Abstract][Full Text] [Related]
15. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
[TBL] [Abstract][Full Text] [Related]
16. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
17. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
18. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
19. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
